AZ's Brilinta Takes Next Step, Gains FDA Approval For Extended Use
This article was originally published in Scrip
Executive Summary
The US FDA has approved AstraZeneca PLC's oral antiplatelet treatment, Brilinta (ticagrelor), in a new indication, allowing the product to be used as a longer term therapy for patients with acute coronary syndrome (ACS).
You may also be interested in...
AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.